Ladenburg Thalmann Financial Services restated their buy rating on shares of BioTime, Inc. (NYSEMKT:BTX) in a report published on Monday morning. Ladenburg Thalmann Financial Services currently has a $6.50 target price on the biotechnology company’s stock, up from their previous target price of $6.00.

A number of other research analysts have also issued reports on BTX. Zacks Investment Research upgraded shares of BioTime from a hold rating to a buy rating and set a $3.50 target price on the stock in a research report on Friday, March 24th. Raymond James Financial, Inc. assumed coverage on shares of BioTime in a report on Friday, March 31st. They set an outperform rating and a $6.00 price target for the company.

Shares of BioTime (BTX) traded up 0.99% on Monday, reaching $3.06. 152,773 shares of the company’s stock were exchanged. The company has a market cap of $339.28 million, a price-to-earnings ratio of 3.16 and a beta of 1.37. BioTime has a 12 month low of $2.26 and a 12 month high of $4.01. The firm’s 50-day moving average price is $3.15 and its 200 day moving average price is $3.28.

COPYRIGHT VIOLATION WARNING: This article was first published by Daily Political and is owned by of Daily Political. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/06/20/biotime-inc-btx-receives-buy-rating-from-ladenburg-thalmann-financial-services.html.

Several hedge funds have recently modified their holdings of the company. Nationwide Fund Advisors increased its stake in shares of BioTime by 2.2% in the first quarter. Nationwide Fund Advisors now owns 44,578 shares of the biotechnology company’s stock worth $154,000 after buying an additional 939 shares during the period. American International Group Inc. increased its position in shares of BioTime by 8.3% in the first quarter. American International Group Inc. now owns 39,794 shares of the biotechnology company’s stock valued at $137,000 after buying an additional 3,036 shares during the last quarter. Metropolitan Life Insurance Co. NY increased its position in shares of BioTime by 14.7% in the first quarter. Metropolitan Life Insurance Co. NY now owns 57,694 shares of the biotechnology company’s stock valued at $199,000 after buying an additional 7,411 shares during the last quarter. Jane Street Group LLC increased its position in shares of BioTime by 19.4% in the first quarter. Jane Street Group LLC now owns 92,685 shares of the biotechnology company’s stock valued at $320,000 after buying an additional 15,080 shares during the last quarter. Finally, Teachers Advisors LLC increased its position in shares of BioTime by 16.8% in the first quarter. Teachers Advisors LLC now owns 120,169 shares of the biotechnology company’s stock valued at $415,000 after buying an additional 17,316 shares during the last quarter.

BioTime Company Profile

BioTime, Inc is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of its cell delivery platform is its HyStem cell and drug delivery matrix technology.

Receive News & Ratings for BioTime Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime Inc. and related companies with MarketBeat.com's FREE daily email newsletter.